A phase I multiple ascending dose (MAD) study of SAGE-217 in healthy volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 29 Jul 2019

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Zuranolone (Primary)
Indications Bipolar depression; Dyskinesias; Essential tremor; Insomnia; Major depressive disorder; Parkinson's disease; Postnatal depression
Focus Adverse reactions; First in man; Pharmacokinetics

24 Jul 2019 Results examining SAGE-217 in single ascending dose (SAD) and multiple ascending dose (MAD) protocols in order to investigate its safety, tolerability, and pharmacokinetic (PK) profiles published in the Clinical Pharmacokinetics
28 Apr 2017 Results assessing safety and tolerability presented at the 69th Annual Meeting of the American Academy of Neurology.
28 Apr 2017 Results of two phase 1 studies assessing pharmacokinetics of SAGE-217 presented at the 69th Annual Meeting of the American Academy of Neurology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com